Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, RemeGen Co's Enterprise Value is €6,311 Mil.
RemeGen Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €6 Mil. Therefore, RemeGen Co's EV-to-OCF for today is 975.21.
The historical rank and industry rank for RemeGen Co's EV-to-OCF or its related term are showing as below:
STU:REG'
s EV-to-OCF Range Over the Past 10 Years
Min: -472 Med: -10.65 Max: 1136.73
Current: 946.28
During the past 8 years, the highest EV-to-OCF of RemeGen Co was 1136.73. The lowest was -472.00. And the median was -10.65.
STU:REG's EV-to-OCF is ranked worse than 99.79% of 1406
companies
in the Biotechnology industry
Industry Median: -3.38
vs STU:REG: 946.28
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RemeGen Co's share price for today is €8.06.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.323.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RemeGen Co EV-to-OCF Related Terms
RemeGen Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for RemeGen Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RemeGen Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where RemeGen Co's EV-to-OCF falls into.
RemeGen Co's current Enterprise Value is €6,311 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (STU:REG) has a EV-to-OCF of 975.21 as of Sep. 14, 2026. According to the industry distribution chart, RemeGen Co ranks #1403 out of 1406 companies in the Biotechnology industry, placing it in the top 99.8%.
Is RemeGen Co's EV-to-OCF too high?
RemeGen Co's current EV-to-OCF is 975.21. Based on the distribution chart, RemeGen Co ranks #1403 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RemeGen Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #1403 out of 1406 companies for EV-to-OCF. This places RemeGen Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. RemeGen Co's current EV-to-OCF is 975.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (STU:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €25.41, compared to a current price of €8.06 — trading 68.3% below its estimated fair value. The current EV-to-OCF is 975.21. RemeGen Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For RemeGen Co (STU:REG), the current EV-to-OCF is 975.21 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (STU:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €8.06 is trading 68.3% below its estimated GF Value™ of €25.41.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for STU:REG:
EV-to-OCF: 975.21
GF Value™: €25.41 vs. price of €8.06 (68.3% below fair value)
No single metric tells the full story. See the STU:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
44GF Score
Get the complete analysis for STU:REG
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:REG has been successfully added to your 
